Synairgen (LON:SNG) Stock Price Down 0.9% – What’s Next?

Synairgen plc (LON:SNG) shares fell 0.9% on Wednesday . The stock traded as low as GBX 2.01 ($0.02) and last traded at GBX 2.23 ($0.03). 81,096 shares were traded during mid-day trading, a decline of 87% from the average session volume of 620,372 shares. The stock had previously closed at GBX 2.25 ($0.03).

Synairgen Trading Down 4.6 %

The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.35 and a current ratio of 6.77. The business’s 50 day moving average price is GBX 3.83 and its 200-day moving average price is GBX 4.06. The firm has a market cap of £4.29 million, a price-to-earnings ratio of -71.00 and a beta of -2.23.

Synairgen Company Profile

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016).